MBIO News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

MB

Mkt Cap

$2.9M

Volume

29.85K

Next Earnings

November 6th

Chart Financials Earnings News About Insider Filings

CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient DemandThe CAR T-cell therapy market for non-Hodgkin's lymphoma is projected to grow at a 7% CAGR from 2026 to 2036, reaching from a 2025 valuation of $3.20 billion across seven major markets. Growth is driven by broader clinical adoption, new indications, earlier-line use, and innovation in autologous and allogeneic platforms. The U.S. dominates with $1.90 billion in 2025 market value, while diffuse large B-cell lymphoma represents the largest patient population with approximately 78,000 cases across the markets.GlobeNewswire Inc. · Sep 16, 2026

Mustang Bio Announces Closing of $8 Million Public OfferingMustang Bio, a clinical-stage biopharmaceutical company, announced the closing of a public offering of common stock and warrants, raising approximately $8 million. The company plans to use the proceeds for working capital and general corporate purposes.GlobeNewswire Inc. · Feb 10, 2025

Mustang Bio Announces Pricing of $8 Million Public OfferingMustang Bio, a clinical-stage biopharmaceutical company, announced the pricing of a public offering of $8 million, which it plans to use for working capital and general corporate purposes.Benzinga · Feb 6, 2025

Mustang Bio Announces Pricing of $8 Million Public OfferingMustang Bio, a clinical-stage biopharmaceutical company, announced the pricing of a public offering of common stock, Series C-1 warrants, and Series C-2 warrants, raising approximately $8 million in gross proceeds.GlobeNewswire Inc. · Feb 6, 2025

Fortress Biotech CEO buys $36.7k in preferred stock - Investing.comFortress Biotech CEO Dr. Lindsay A. Rosenwald has increased his stake in the company by purchasing $36.7k worth of Series A Cumulative Perpetual Preferred Stock. This move demonstrates the CEO's confidence in the company's future prospects.Investing.com · Jul 10, 2024

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesWORCESTER, Mass., June 21, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules, for the issuance and sale of an aggregate of 6,130,000 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.41 per share (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Mustang also issued unregistered warrants to purchase up to an aggregate of 6,130,000 shares of its common stock. The unregistered warrants have an exercise price of $0.41 per share, are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants and will expire five years from the date of stockholder approval.GlobeNewswire Inc. · Jun 21, 2024

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesWORCESTER, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 6,130,000 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.41 per share (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Mustang has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 6,130,000 shares of its common stock. The offering is expected to close on or about June 21, 2024, subject to the satisfaction of customary closing conditions.GlobeNewswire Inc. · Jun 20, 2024

Navigating Bull and Bear Penny Stocks Markets, 3 TipsUse these top tips to navigate the bull and bear penny stocks market The post Navigating Bull and Bear Penny Stocks Markets, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.PennyStocks · Jun 20, 2024

Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer StudyUpdated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell therapy achieved an overall response rate of 90% in patients with a rare form of blood cancer.Zacks Investment Research · Jun 18, 2024

What 3 Factors Impact Penny Stocks Prices the MostHere are the 3 factors that impact penny stocks more than others The post What 3 Factors Impact Penny Stocks Prices the Most appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.PennyStocks · Jun 18, 2024

MB

MBIOMustang Bio, Inc.

MBIO

Pay with—

Available Balance0.00

Your PositionYou don't own any MBIO yet.

Related Tickers

Earnings